Vanda Pharmaceuticals Inc (Vanda) is a biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs. The company utilizes technologies such as genetics and genomics in drug discovery, clinical trials, and commercial positioning. Vanda's primary activities include the development of medicines for conditions like bipolar disorder, schizophrenia, sleep-wake disorders, multiple sclerosis, and motion sickness.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Vanda’s R&D efforts focus on developing novel therapies to address high unmet medical needs. The company collaborates with third parties for preclinical research and utilizes multiple clinical sites for trials. A significant collaboration is with OliPass Corporation to develop ASO molecules for gene expression modification. The company is also advancing several pipeline products, including Fanapt, Bysanti, Hetlioz, Ponvory, Nereus, Imsidolimab, VTR-297, VSJ-110, and VQW-765, targeting various medical conditions. In FY2025, the company incurred R&D expense of US$109.3 million, which as a percentage of revenue stood at 50.6% and grew 46.9% YoY. Vanda holds patents and patent applications for products like Ponvory, Nereustm, and VQW-765, and has sought NCE patent protection for Bysanti, VTR-297, and CFTR activators and inhibitors.